Browse studies
Find your next paid study
4 recruiting studies matching your filters
A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer …
Non-Muscle Invasive Bladder Neoplasms
Estimated
~$10 – $1,050
Janssen Research & Development, LLCNCT07309445
Phase 3
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or…
Non-Muscle Invasive Bladder Neoplasms
Estimated
~$10 – $8,750
Janssen Research & Development, LLCNCT06919965
Phase 3
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of in…
Non-Muscle Invasive Bladder Neoplasms
Estimated
~$10 – $8,750
Janssen Research & Development, LLCNCT06319820
Phase 2
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the…
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ
Estimated
~$10 – $8,750
Merck Sharp & Dohme LLCNCT06833073